Measurements of the pons as a biomarker of progression for pediatric DIPG

Emilie A Steffen-Smith1, Eva H Baker, David Venzon

  • 1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10/Room 1-5750, 9000 Rockville Pike, Bethesda, MD, 20892, USA, steffene@mail.nih.gov.

Journal of Neuro-Oncology
|October 12, 2013
PubMed

Insights

Measuring the pons, not the tumor, offers a reliable method to track diffuse intrinsic pontine glioma (DIPG) progression. These pons measurements are a viable in vivo biomarker for predicting patient outcomes.

Area of Science:

  • Pediatric Oncology
  • Neuro-oncology
  • Medical Imaging

Background:

  • Diffuse intrinsic pontine glioma (DIPG) treatment is challenging due to a lack of reliable response biomarkers.
  • Current tumor measurement methods for DIPG lack standardization and are not predictive of outcomes, showing significant inter-observer variability.

Purpose of the Study:

  • To evaluate the reliability and prognostic value of one-dimensional (1D) and two-dimensional (2D) pons measurements using anatomical landmarks in pediatric DIPG patients.
  • To establish a standardized, in vivo biomarker for DIPG response assessment.

Main Methods:

  • Longitudinal MRI data from 75 DIPG patients were analyzed.
  • Four readers independently performed 1D and 2D measurements of the pons using anatomical landmarks on FLAIR images.
  • Inter-reader agreement and variability were assessed using differences and coefficient of variation (CV); prognostic value was determined using Cox proportional hazards models.

Main Results:

  • Strong agreement and low inter-reader variability were observed for both 1D and 2D pons measurements (median CV = 3.1% and 4.8%, respectively).
  • Increases in pons measurements over time significantly correlated with poorer prognosis and shorter overall survival (RH = 2.29 for 1D, RH = 1.13 for 2D).
  • Pons measurements demonstrated lower inter-reader variability compared to traditional tumor measurement techniques.

Conclusions:

  • One-dimensional and two-dimensional measurements of the pons using anatomical landmarks are reliable and reproducible in DIPG patients.
  • Pons measurements serve as a viable in vivo biomarker, correlating with patient outcomes and offering a standardized approach for assessing DIPG.
  • This novel measurement technique can aid in evaluating treatment efficacy and improving prognostic accuracy in pediatric DIPG.

Related Concept Videos